[Clinical significance of ROS1 rearrangements in non-small cell lung cancer].

摘要: Chromosomal rearrangements involving the ROS1 receptor tyrosine kinase gene have recently been described in multiple malignancies, including non-small cell lung cancer (NSCLC). rearrangement defines a new molecular subset of NSCLC with prevalence around 1%-2%. ROS1-positive NSCLCs arise young never-smokers adenocarcinoma that are similar to those observed patients ALK-rearranged NSCLC. Crizotinib demonstrates vitro activity and early clinical trial shows marked antitumor ROS1-rearranged patients. The overall response rate is 56% disease control at 8 weeks about 76%. Further understanding fusions pathogenesis NSCLC, methods detect rearrangements, targeting specific inhibitors would lead an era personalized medicine.